Navigation Links
Genome editing, a next step in genetic therapy, corrects hemophilia in animals
Date:6/26/2011

advantage over conventional gene therapy techniques that may randomly deliver a replacement gene into an unfavorable location, bypassing normal biological regulatory components controlling the gene. This imprecise targeting carries a risk of "insertional mutagenesis," in which the corrective gene causes an unexpected alteration, such as triggering leukemia.

In hemophilia, an inherited single-gene mutation impairs a patient's ability to produce a blood-clotting protein, leading to spontaneous, sometimes life-threatening bleeding episodes. The two major forms of the disease, which occurs almost solely in males, are hemophilia A and hemophilia B, caused respectively by a lack of clotting factor VIII and clotting factor IX. Patients are treated with frequent infusions of clotting proteins, which are expensive and sometimes stimulate the body to produce antibodies that negate the benefits of treatment.

In the current study, the researchers used genetic engineering to produce mice with hemophilia B, modeling the disease in people. Before treatment, the mice had no detectable levels of clotting factor IX.

Previous studies by other researchers had shown that ZFNs could accomplish genome editing in cultured stem cells that were then injected into mice to treat sickle cell disease. However, this ex vivo approach is not feasible for many human genetic diseases, which affect whole organ systems. Therefore the current study tested whether genome editing was effective when directly performed in vivo (in a living animal).

High and colleagues designed two versions of a vector, or gene delivery vehicle, using adeno-associated virus (AAV). One AAV vector carried ZFNs to perform the editing, the other delivered a correctly functioning version of the F9 gene. Because different mutations in the same gene may cause hemophilia, the process replaced seven different coding sequences, covering 95 percent of the disease-carrying mutations in hemophilia B.'/>"/>

Contact: John Ascenzi
ascenzi@email.chop.edu
267-426-6055
Children's Hospital of Philadelphia
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. The human genome -- now on an iPad near you
2. The complete map of the Germany E. coli O104 genome released
3. Entomologists launch the 5,000 Insect Genome Project (i5k)
4. Genome offers clue to functions of destructive wheat fungus
5. Genome sequence could reveal Achilles heels of important wheat disease
6. Gerry A. Higgins, Ph.D. Joins GenomeQuest to Foster Development of Whole Genome Diagnostics
7. Einstein offers easy-to-use genome analyzer to scientific community
8. BGI releases a complete de novo E. coli O104 genome and details of their detection kit
9. BGI sequences genome of the deadly E. coli in Germany and reveals new super-toxic strain
10. Of mice and men: UNC-led team solves mouse genome dilemma
11. Comparison of genomes of plant parasites provides solid clues for response
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Genome editing, a next step in genetic therapy, corrects hemophilia in animals
(Date:9/18/2014)... A team of researchers from McGill University and ... form of polyethylene ,microbeads, Canadian Journal of ... likely originate from cosmetics, household cleansers, or industrial ... abrasives. Owing to their small size and buoyancy, ... Microplastics are a global contaminant in the ...
(Date:9/18/2014)... DNA, tiny strands of nucleic acid that contain instructions ... genetic data, our DNA is copied into RNA molecules, ... tasks in our cells. , Several years ago, ... all other known RNAs, this molecule is circular, and ... little has been known about how they are produced. ...
(Date:9/18/2014)... from several disciplines will be celebrated tonight at the ... in improving the health of premature infants and in ... The researchers, whose work was supported by the National ... former Atomic Energy Commission, will be honored at a ... A bipartisan group of Members of Congress will be ...
Breaking Biology News(10 mins):Microplastic pollution discovered in St. Lawrence River sediments 2Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 23rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2
... that rising global temperatures accompanied by melting permafrost in ... into the atmosphere. Once released, that methane gas would ... radiation about 20 times more efficiently than does the ... appearing in the Journal of Geophysical Research ...
... that specially synthesized boron compounds are readily accepted in ... a proof of concept that could lead to new ... Oregon chemist Shih-Yuan Liu reported in the Journal ... of boron-nitrogen compounds with electronic and structural similarities to ...
... This release is available in German . ... restoration and maintenance of the Earth,s multi-trillion dollar ecosystems - ... can have a key role in countering climate change and ... of a new climate issues update by The Economics of ...
Cached Biology News:Methane gas likely spewing into the oceans through vents in sea floor 2Methane gas likely spewing into the oceans through vents in sea floor 3Boron-based compounds trick a biomedical protein 2Time to tap climate-change-combating potential of the world's ecosystems 2Time to tap climate-change-combating potential of the world's ecosystems 3Time to tap climate-change-combating potential of the world's ecosystems 4Time to tap climate-change-combating potential of the world's ecosystems 5
(Date:9/19/2014)... 19, 2014  Nektar Therapeutics (NASDAQ: ... characterizing the analgesic profiles of a series of ... agonist molecules. The preclinical research candidates were created ... The analgesic properties of kappa receptor ... 1,2 Kappa opioid receptors are expressed in ...
(Date:9/19/2014)... Dublin ... announced the addition of the  "Micro Market Monitor ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... fastest-growing segments in the chromatography market. The market ... expected to reach $2.0 billion by 2019, at ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... near-patient testing, is performed outside a clinical laboratory. ... hence in administrating appropriate treatments and medication. POCT ... and prevalence of lifestyle diseases such as diabetes, ... and user-friendly. POCT devices are standardized to minimize ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Texas ... John Sharp, Texas A&M Health Science Center CEO ... Department of Health and Human Services (HHS), State ... a national pandemic influenza vaccine manufacturing facility in ... an anchor for the Texas A&M Biocorridor – ...
Breaking Biology Technology:Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Micro Market Monitor : Global Pre-packed Chromatography Columns 2POCT Market in China 2014-2018 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4
... ... PharmSource Information Services, Inc. announces the publication of a ... How to Minimize Your Risk." This incisive resource provides guidelines on ... risk for companies doing business throughout the world. "The U.S. Foreign ...
... SAN DIEGO, INDIANAPOLIS and CAMBRIDGE, Mass., July 7 ... Lilly and Company (NYSE: LLY ) and Alkermes, ... New Drug Application (NDA) for exenatide once weekly has been ... (FDA). , , Exenatide once weekly is an investigational ...
... Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: ... Sun Pharmaceutical Industries Ltd. (Sun Pharma), immediately following Sun ... Drug Administration (FDA) for its Abbreviated New Drug Application ... tablets are an androgen receptor inhibitor indicated for use ...
Cached Biology Technology:PharmSource Releases White Paper on Role of U.S. Foreign Corrupt Practices Act (FCPA) in the Bio/Pharma Industry 2PharmSource Releases White Paper on Role of U.S. Foreign Corrupt Practices Act (FCPA) in the Bio/Pharma Industry 3New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 2New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 3New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 4New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 5New Drug Application for Exenatide Once Weekly Accepted for Review by FDA 6Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Casodex(R) Tablets 2